Recent studies are revealing the potential of GLP-1 receptor agonists, commonly used as weight loss medications, to address various substance use disorders, including addiction to alcohol, opioids, cocaine, nicotine, and more. Research involving 600,000 individuals indicates that these drugs may substantially lower the risk of addiction and substance-related mortality, especially among populations such as U.S. veterans. The findings suggest that GLP-1 medications could curtail cravings and may serve as innovative treatments for addiction, marking a significant development in the intersection of obesity management and substance abuse treatment.